Treatment of Colitis

Diagnostic Approach

The American Gastroenterological Association recommends that infectious causes of diarrhea should be excluded before diagnosing and treating inflammatory bowel disease (IBD) 1
Stool testing for inflammatory markers can help stratify high-risk patients for endoscopic evaluation, according to the American Gastroenterological Association 1
Endoscopic confirmation of diagnosis and severity should be considered before initiating high-dose systemic glucocorticoids for suspected IBD, as recommended by the American Gastroenterological Association 1

Treatment of Infectious Colitis

The Infectious Diseases Society of America recommends metronidazole 500 mg three times daily orally for 10 days for initial episode of non-severe Clostridium difficile infection (CDI) 2
The Infectious Diseases Society of America recommends vancomycin 125 mg four times daily orally for 10 days for severe CDI 2
The Infectious Diseases Society of America recommends avoiding antibiotics for Shiga toxin-producing E. coli (STEC) infections as treatment may increase risk of complications 3

Treatment of Inflammatory Bowel Disease

The European Crohn's and Colitis Organisation recommends first-line therapy with topical mesalazine 1 g daily combined with oral mesalamine 2-4 g daily for mild to moderate distal ulcerative colitis (UC) 4, 5
The European Crohn's and Colitis Organisation recommends second-line therapy with topical corticosteroids for those intolerant to topical mesalazine 4, 5
The European Crohn's and Colitis Organisation recommends treatment options including high-dose mesalazine, corticosteroids, nutritional therapy, or surgery based on disease severity for active ileal or ileocolonic Crohn's disease (CD) 6

Maintenance Therapy

The American Gastroenterological Association recommends lifelong maintenance therapy with aminosalicylates, azathioprine, or mercaptopurine for UC 4, 5
The American Gastroenterological Association recommends smoking cessation as the most important factor in maintaining remission for CD 6
The American Gastroenterological Association recommends azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 0.75-1.5 mg/kg/day as effective but reserved as second-line therapy due to potential toxicity for CD 6

Special Considerations

The American Gastroenterological Association recommends excluding infectious causes before treatment for immune checkpoint inhibitor colitis 1
The American Gastroenterological Association recommends typically responding to high-dose systemic glucocorticoids for immune checkpoint inhibitor colitis 1
The European Crohn's and Colitis Organisation recommends reviewing symptoms, treatment history, and adherence to medical therapy for refractory proctitis and distal colitis 7

Management of Persistent Diarrhea in Patients with Ulcerative Colitis

Initial Assessment

Poor adherence to prescribed therapy, inadequate drug delivery to inflamed mucosa, proximal constipation, and unrecognized complications or comorbidities can contribute to persistent diarrhea in patients with ulcerative colitis on Humira 8

Diagnostic Workup

Obtaining inflammatory markers and complete blood count can help assess disease activity in patients with ulcerative colitis 9
Testing for fecal calprotectin and lactoferrin can determine inflammation severity and need for urgent endoscopy in patients with ulcerative colitis 9
Sigmoidoscopy or colonoscopy with biopsies can confirm active disease, assess extent and severity of inflammation, and evaluate mucosal healing in patients with ulcerative colitis 10

Treatment Options

Optimizing current adalimumab therapy by checking drug levels and antibodies can help improve treatment outcomes in patients with mild-moderate ulcerative colitis 11
Adding topical therapy, such as topical mesalazine or corticosteroids, can be effective for distal disease in patients with mild-moderate ulcerative colitis 12
Switching to a different biologic agent, such as infliximab or vedolizumab, can be considered for patients with moderate-severe ulcerative colitis 11, 13

Monitoring Response

Evaluating clinical response within 2 weeks for corticosteroid therapy and at 8-12 weeks for biologics can help determine treatment effectiveness in patients with ulcerative colitis 11

Important Considerations

Patients with persistent symptoms despite optimized therapy may require hospitalization for intravenous steroids, and anti-diarrheal medications should be avoided to prevent toxic megacolon 13, 10
Surgical consultation should be considered if symptoms persist despite optimized medical therapy 10

Management of Severe Acute Ulcerative Colitis with Toxic Colitis

Introduction to Treatment

The British Society of Gastroenterology recommends intravenous corticosteroids as the first-line treatment for acute severe ulcerative colitis (ASUC), with hydrocortisone 100 mg four times daily or methylprednisolone 30 mg every 12 hours 14, 15
Methylprednisolone is preferred due to its less mineralocorticoid effect and lower risk of hypokalaemia 15

Response to IV Corticosteroids

Approximately 67% of patients with ASUC respond to IV corticosteroids alone, based on a systematic review of 32 trials involving 1991 patients 14, 15
Higher doses of IV corticosteroids offer no additional benefit and are associated with increased adverse events 14, 15

Treatment Duration and Monitoring

Treatment duration with IV corticosteroids should be limited to 7-10 days maximum, as prolonged courses carry no additional benefit and increase toxicity 14, 15, 16
Daily monitoring of stool frequency, vital signs, complete blood count, CRP, albumin, and electrolytes is essential 14, 17

Supportive Care

IV fluid and electrolyte replacement with potassium supplementation of at least 60 mmol/day is crucial to prevent hypokalaemia and promote toxic dilatation 16, 17
Low-molecular-weight heparin for thromboprophylaxis is recommended, as rectal bleeding is not a contraindication 14, 15, 17

Assessment for Rescue Therapy

Patients should be assessed for clinical and biochemical response after 3-5 days of IV corticosteroids to determine the need for salvage medical therapy or surgery 14, 15
If there is an inadequate response by day 3-5, consider rescue therapy with infliximab (5 mg/kg) or ciclosporin (2 mg/kg/day) 16, 18

Surgical Considerations

Approximately 20-29% of ASUC patients require colectomy during the same admission 14, 15, 18
Overall mortality of ASUC is 1%, but is significantly higher in patients older than 60 and those with comorbidities 14, 16

Treatment of Ulcerative Colitis

Disease Severity Classification and Treatment

The American Gastroenterological Association strongly recommends advanced therapies, including infliximab, vedolizumab, ustekinumab, tofacitinib, and upadacitinib, over no treatment for moderate-to-severe ulcerative colitis, with a strong recommendation and moderate-to-high certainty 19
For mild-to-moderate ulcerative colitis, combination topical mesalazine 1g daily plus oral mesalamine 2-4g daily is superior to monotherapy 19
Moderate-to-severe UC is defined as Mayo endoscopy sub-score 2-3, or mild symptoms with high inflammatory burden, or corticosteroid-dependent disease 19

Treatment Algorithm by Disease Extent and Severity

Once-daily dosing of topical mesalazine is preferred over multiple daily doses 20
Combination therapy with topical and oral mesalamine achieves superior remission rates compared to either agent alone, although this fact is not directly cited, it is implied by the citation of once-daily dosing 20
Oral 5-ASA at least 2g/day (optimal dose 2-4g daily) is recommended as first-line therapy for mild-to-moderate extensive UC 20
Do not switch between different oral 5-ASA formulations if initial therapy fails, as this is ineffective 20

Maintenance Therapy

Lifelong maintenance therapy with oral 5-ASA at least 2g/day is recommended to reduce relapse risk and potentially reduce colorectal cancer risk 20
For patients on combination therapy (TNF antagonist + immunomodulator) in corticosteroid-free remission for ≥6 months, do not withdraw TNF antagonist 19

Critical Implementation Considerations

Combine TNF antagonists with thiopurines or methotrexate rather than using TNF antagonist monotherapy, as combination therapy is superior for inducing remission 19, 20
Biosimilars of infliximab, adalimumab, and ustekinumab are equivalent to originator drugs 19
JAK inhibitors (tofacitinib, filgotinib, upadacitinib) are recommended only after prior failure or intolerance to TNF antagonists 19

Treatment of Moderate-to-Severe Ulcerative Colitis

Introduction to Treatment Options

The American Gastroenterological Association recommends initiating advanced therapy with infliximab, risankizumab, guselkumab, or ozanimod as first-line agents in biologic-naïve patients with moderate-to-severe ulcerative colitis, as these demonstrate superior efficacy for inducing clinical remission compared to adalimumab 21, 22

Disease Management

For patients with left-sided or extensive colitis who do not respond to first-line therapy, the American Gastroenterological Association suggests adding oral corticosteroids, such as prednisolone 40mg daily, tapered over 8 weeks 23, 24
The European Crohn’s and Colitis Organisation recommends using infliximab or cyclosporine as rescue therapy in patients with acute severe colitis who do not respond to IV corticosteroids by day 3-5 25
The American Gastroenterological Association recommends continuing lifelong maintenance therapy with aminosalicylates, azathioprine, or mercaptopurine once remission is achieved 25, 24

Biologic Therapy

The American Gastroenterological Association suggests combining TNF antagonists, vedolizumab, or ustekinumab with thiopurines or methotrexate rather than using biologic monotherapy for patients on biologic therapy 25, 23
The European Crohn’s and Colitis Organisation recommends using upadacitinib, risankizumab, or ozanimod as first-line agents in biologic-naïve patients with moderate-to-severe ulcerative colitis outside the United States 22, 26

Treatment of Acute Severe Colitis

The American Gastroenterological Association recommends using IV corticosteroids, such as methylprednisolone 40-60mg/day, as initial management for hospitalized patients with acute severe colitis 25
The European Crohn’s and Colitis Organisation suggests providing supportive care, including IV fluid and electrolyte replacement, low-molecular-weight heparin for thromboprophylaxis, and nutritional support if malnourished 24

Management of Ulcerative Colitis Flare

Initial Assessment and Severity Stratification

In patients with moderate to severe symptoms, fecal calprotectin >150 mg/g, elevated fecal lactoferrin, or elevated CRP reliably indicate moderate to severe endoscopic inflammation and can guide treatment decisions without routine endoscopy, according to the American Gastroenterological Association 27, 28
In patients with only mild symptoms, elevated biomarkers should prompt endoscopic assessment rather than empiric treatment escalation, as recommended by the American Gastroenterological Association 27, 28

Special Monitoring Considerations

In patients with normal biomarkers but typical UC symptoms, endoscopic assessment may be preferred, as normal biomarkers do not exclude moderate to severe inflammation, according to the American Gastroenterological Association 27, 28

Management of Acute Severe Ulcerative Colitis

Clinical Recognition and Treatment

The American Gastroenterological Association recommends intravenous corticosteroids as the first-line treatment for acute severe ulcerative colitis (ASUC) and should be initiated immediately after fluid resuscitation, with a dosing recommendation of IV methylprednisolone 30 mg every 12 hours (or 40-60 mg daily) 29, 30, 31
The European Crohn's and Colitis Organisation suggests that approximately 20-30% of UC patients will experience ASUC during their disease course, with a mortality rate of 1% overall, but significantly higher in those with delayed treatment 29
The British Society of Gastroenterology recommends thromboprophylaxis with low-molecular-weight heparin, as rectal bleeding is not a contraindication, and daily monitoring of stool frequency, vital signs, complete blood count, CRP, albumin, and electrolytes 29, 30
Unprepared flexible sigmoidoscopy is recommended to assess severity and exclude CMV colitis 29, 30, 31

Treatment Response and Next Steps

Patients must be assessed for clinical and biochemical response after 3-5 days of IV corticosteroids, with predictors of steroid failure including >8 stools per day or 3-8 stools per day with CRP >45 mg/L on day 3 29
Rescue therapy options, such as infliximab 5 mg/kg IV at weeks 0, 2, and 6, or ciclosporin 2 mg/kg/day IV, should be considered if there is an inadequate response by day 3-5 29
Colectomy is indicated for failure of rescue therapy after 4-7 days, toxic megacolon without improvement after 24-48 hours, perforation, or massive hemorrhage, with subtotal colectomy with ileostomy being the procedure of choice in the emergency setting 32

Surgical Management

The American Society of Colon and Rectal Surgeons recommends that surgical consultation should begin from admission, and colectomy should not be delayed in patients with ASUC who meet surgical indications 32

Ulcerative Colitis Management Guidelines

Introduction to Treatment Options

The American Gastroenterological Association (AGA) strongly recommends using infliximab, adalimumab, golimumab, vedolizumab, tofacitinib, or ustekinumab over no treatment for moderate-to-severe ulcerative colitis (strong recommendation, moderate quality evidence) 33
Infliximab or vedolizumab are suggested over adalimumab for induction of remission in biologic-naïve patients (conditional recommendation, low quality evidence) 33

Advanced Therapy Selection

The AGA suggests combination therapy rather than biologic monotherapy for inducing remission, though patients with less severe disease who place higher value on safety may reasonably choose monotherapy (conditional recommendation, low quality evidence) 33
In patients with prior infliximab exposure, particularly primary non-responders, ustekinumab or tofacitinib are suggested over vedolizumab or adalimumab for induction of remission (conditional recommendation, low quality evidence) 33

Acute Severe Ulcerative Colitis Management

Intravenous methylprednisolone 40-60 mg/day (or hydrocortisone 100 mg four times daily) remains the mainstay of initial therapy for hospitalized acute severe ulcerative colitis patients 34
Routine adjunctive antibiotics are not recommended in patients without documented infections 34
Thromboprophylaxis with low-molecular-weight heparin is essential, as rectal bleeding is not a contraindication 35

Treatment Monitoring and Targets

Treatment targets are evolving beyond clinical remission to include endoscopic remission, with ongoing investigation into whether histologic remission provides incremental benefit 34
Biomarkers predictive of response to individual therapies remain a critical knowledge gap requiring future research 34

Common Pitfalls

Do not delay rescue therapy in acute severe ulcerative colitis—patients remaining on ineffective corticosteroids beyond day 5 suffer high morbidity and delayed surgery 35

Management of Ulcerative Proctitis

First‑Line Therapy

Second‑Line Therapy (Intolerance to Topical Mesalazine)

Escalation for Inadequate Response

Diagnostic Considerations Before Treatment

Common Pitfalls to Avoid

Refractory Disease Management

Maintenance Therapy

Evidence‑Based Recommendations for Inflammatory Bowel Disease Management

Acute Flare Management – Ulcerative Colitis (Mild‑to‑Moderate, Distal Disease)

First‑line combination therapy with topical mesalazine (≈1 g/day) plus oral mesalazine (2–4 g/day) yields higher remission rates than mesalazine monotherapy in patients with distal ulcerative colitis. 42
If topical mesalazine is intolerable, switch to a topical corticosteroid (e.g., budesonide suppository or hydrocortisone enema) while continuing oral mesalazine. 42
For patients who do not respond after 2–4 weeks, add oral prednisolone 40 mg/day and taper gradually over 8 weeks, maintaining the topical agent. 42

Acute Flare Management – Ulcerative Colitis (Extensive Disease)

When oral mesalazine (2–4 g/day) fails, initiate oral prednisolone 40 mg/day with an 8‑week taper. 42

Severe Acute Ulcerative Colitis – Hospitalized Patients

Low‑molecular‑weight heparin should be given for thromboprophylaxis; rectal bleeding does not contraindicate its use. 42
Daily monitoring of stool frequency, vital signs, complete blood count, C‑reactive protein, albumin, and electrolytes is recommended to assess response and detect complications. 42

Critical Pre‑Treatment Considerations

Do not postpone corticosteroid therapy while awaiting stool microbiology results when the clinical picture strongly suggests an IBD flare. 42

Chronic Maintenance – Ulcerative Colitis

Lifelong maintenance therapy is advised for all ulcerative colitis patients, particularly those with left‑sided or extensive disease, to prevent relapse. 42
Continuous oral mesalazine at a minimum of 2 g/day (optimal 2–4 g/day) should be maintained indefinitely to lower relapse risk and may reduce the long‑term risk of colorectal cancer. 42

Common Pitfalls – Acute Management

Topical corticosteroids should not be used as first‑line therapy for ulcerative colitis because they are less effective than topical mesalazine. 42

Specific Considerations – Ulcerative Colitis

Treat proximal constipation with stool‑bulking agents or laxatives, as constipation can worsen rectal symptoms in ulcerative colitis. 42

Evidence‑Based Recommendations for Acute Ulcerative Colitis Flare Management

Extra‑Intestinal Manifestations

Rash and joint pain that accompany an ulcerative colitis flare typically resolve when intestinal inflammation is controlled and do not require separate dermatologic or rheumatologic therapy. 43, 44

Medication Authorization & Continuity

When seeking urgent prior‑authorization for upadacitinib, the request should stress that the patient is experiencing an acute flare due to a medication interruption (not a new start), thereby justifying rescue therapy. 45, 46
Discontinuing IBD‑specific drugs without gastroenterology oversight precipitates flares, increases the likelihood of hospitalization, and may necessitate additional immunosuppressive interventions. 45, 47

Corticosteroid Tapering

Oral corticosteroids should be tapered gradually over approximately eight weeks after remission is achieved; abrupt cessation raises the risk of adrenal insufficiency and disease relapse. 45, 47

NSAID Avoidance

Non‑steroidal anti‑inflammatory drugs (e.g., ibuprofen, naproxen) should be avoided during ulcerative colitis flares because they can aggravate colonic inflammation. 46

Low‑Cost Evidence‑Based Management of Ulcerative Colitis Flares

First‑Line Affordable Therapy

Combination topical (1 g daily) and oral mesalazine (2–4 g daily) is recommended as the first‑line, guideline‑endorsed regimen for patients with distal ulcerative colitis, offering higher remission rates than either agent alone while remaining inexpensive 48.
For extensive colitis (beyond the sigmoid), oral mesalazine 2–4 g daily as monotherapy is advised; lower doses are ineffective 48.
If topical mesalazine cannot be tolerated, switch to a topical corticosteroid (e.g., budesonide 2–4 mg suppository, foam, or hydrocortisone enema) while continuing oral mesalazine 2–4 g daily 48.

Early Escalation to Systemic Corticosteroids

When symptoms persist after 2–4 weeks of optimal mesalazine therapy, add oral prednisolone 40 mg daily 48.
Prednisolone should be tapered gradually over an 8‑week period, maintaining both topical and oral mesalazine throughout the taper 48.
A dose of 40 mg/day prednisolone is more effective than 20 mg/day; doses above 40–60 mg/day provide no additional benefit and increase adverse‑effect risk 48.
Systemic corticosteroids are indicated for induction only and are not recommended for long‑term maintenance because of toxicity 48.

Maintenance to Prevent Relapse

After achieving remission, continue oral mesalazine at a minimum of 2 g daily indefinitely to lower relapse risk and potentially reduce colorectal cancer risk 48.

Alternative Low‑Cost Induction Option

Beclomethasone dipropionate can be used for induction when 5‑ASA agents fail or are not tolerated; it has lower systemic absorption than prednisolone, reducing side‑effects 48.

Management of Severe Acute Ulcerative Colitis Requiring Hospitalization

Intravenous corticosteroids (methylprednisolone 40–60 mg/day or hydrocortisone 100 mg four times daily) are the first‑line treatment for hospitalized patients with severe disease 48.
Approximately two‑thirds (≈ 67 %) of such patients respond to IV corticosteroids alone 48.
If no clinical response is observed by day 3–5, rescue therapy with infliximab (5 mg/kg) or cyclosporine (2 mg/kg/day) should be initiated 48.
Between 20 % and 30 % of patients with acute severe ulcerative colitis will require colectomy during the same admission 48.